

1645



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

COPY OF PAPERS
ORIGINALLY FILED

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM


DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

July 24, 2002

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
July 24, 2002	
Date	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/010,763 entitled "METHODS FOR DETECTING THE EFFICACY OF ANTICANCER TREATMENTS" by Isaiah J. Fidler and Corazon D. Bucana*
Our Reference: UTSC:684US
Client Reference: MDA00-053


Sir:

Enclosed for filing in the above-referenced patent application is a Supplemental Information Disclosure Statement, Form PTO-1449, and references (A4, C31-C33).

No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:684US.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted
25189805.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Isaiah J. Fidler
Corazon D. Bucana

Serial No.: 10/010,763

Filed: November 2, 2001

For: METHODS FOR DETECTING THE
EFFICACY OF ANTICANCER
TREATMENTS




Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: UTSC:684USTECH CENTER 1600/2900

RECEIVED

AUG 01 2002

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
July 24, 2002	
Date	Steven D. Highlander

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be

construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/UTSC:684US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,




Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: July 24, 2002

Form PTO-1449 (modified)		Atty. Docket No. UTSC:684US	Serial No. 10/010,763
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Isaiah J. Fidler Corazon D. Bucana	
		Filing Date: November 2, 2001	Group: 1645
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	



U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A4	5,480,968	1/2/96	Kraus <i>et al.</i>	530	326	11/10/92

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C31	Albanell <i>et al.</i> , "Pharmacodynamic studies of the specific oral EGFR tyrosine kinase inhibitor (EGFR-TKI) zd1839 ('Iressa') in skin from cancer patients participating in phase I trials: histopathological and molecular consequences of receptor inhibition," <i>European Journal of Cancer</i> , 37(Supp. 6): S159, 2001.
	C32	Parker <i>et al.</i> , "Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice," <i>J. of Histochemistry and Cytochemistry</i> , 46(5):595-602, 1998.
	C33	Pollack <i>et al.</i> , "Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice," <i>J. Pharmacology and Experimental Therapeutics</i> , 291(2):739-748, 1999.

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 01 2002

TECH CENTER 1600/2900

25189785.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)